UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000032737
Receipt No. R000036924
Scientific Title Efficacy and safety of etanercept for non-infectious lung complications after allogeneic stem cell transplantation
Date of disclosure of the study information 2018/06/01
Last modified on 2020/06/04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Efficacy and safety of etanercept for non-infectious lung complications after allogeneic stem cell transplantation
Acronym Etanercept for non-infectious lung complications after allogeneic stem cell transplantation
Scientific Title Efficacy and safety of etanercept for non-infectious lung complications after allogeneic stem cell transplantation
Scientific Title:Acronym Etanercept for non-infectious lung complications after allogeneic stem cell transplantation
Region
Japan

Condition
Condition Non-infectious lung complications after allogeneic stem cell transplantation
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate efficacy and safety of etanercept for patients with non-infectious lung complications after allogeneic stem cell transplantaion
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Primary endpoint is the complete response rate at day 28 after administration of etanercept. The complete response rate is defined as the percentage of the patients with SpO2 93% or above on room air for 72 hours or above. The patients with SpO2 93% or above on room air after day 26 will be assessed after 72 hours from the achievement of SpO2 93% or above.
Key secondary outcomes 1. Response rate at day 28 after administration of etanercept
The response rate is included in the complete response rate and the partial response rate. The partial response rate is defined as the percentage of the patients with SpO2 93% or above for 72 consecutive hours by at least 50% or below of oxygen support requirements before the start of treatment.
2. Duration from the start of treatment until the first day of independent of oxygen support for 72 hours
3. Overall survival at day 28 and 1 year after the start of treatment
4. Adverse effect such as infection and reaction on injection site, laboratory data and the results of X-ray and CT scan
5. The levels of cytokines prior to administration of etanercept, at day 15 days and day 29 after treatment, and the association between these data and response rate
6.The association between patient characteristics and response rate

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification NO
Dynamic allocation NO
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Etanercept is administered subcutaneously at a dose of 25mg/body, twice weekly (72-96 hours between doses), for total of 8 doses (4-week course).
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
16 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patients older than 16 years
2. Signed informed consent by patients themselves or their proxies to participate as a subject in this study
3. Patients with non-infectious lung complications after allogeneic stem cell transplantation and an oxygen saturation (SpO2) 93% or below in room air or 93% or above in inhaled oxygen
Key exclusion criteria 1. Patients who do not consent to this study
2. Patients considered ineligible for this study by physicians
Target sample size 20

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takaaki Ono
Organization Hamamatsu university school of medicine
Division name Department of hematology
Zip code
Address 1-20-1 Hanndayama, Higashi-ku, Hamamatsu 431-3192, Japan
TEL 053-435-2267
Email takaono@hama-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Miwa Adachi
Organization Hamamatsu university school of medicine
Division name Department of hematology
Zip code
Address 1-20-1 Hanndayama, Higashi-ku, Hamamatsu 431-3192, Japan
TEL 053-435-2267
Homepage URL
Email m.adachi@hama-med.a.cjp

Sponsor
Institute Department of hematology, Hamamatsu university school of medicine
Institute
Department

Funding Source
Organization Department of hematology, Hamamatsu university school of medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 06 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2018 Year 01 Month 09 Day
Date of IRB
2020 Year 04 Month 07 Day
Anticipated trial start date
2018 Year 06 Month 01 Day
Last follow-up date
2020 Year 03 Month 19 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 05 Month 28 Day
Last modified on
2020 Year 06 Month 04 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036924

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.